Global /India /Healthcare /Drug Manufacturers - Specialty & Generic /CIPLA
chevron_leftBack

Cipla Ltd.

CIPLA
NSE: CIPLA Delayed
1,533.70INR 0.4%
17.94 USD
As of 24 April 2025, Cipla Ltd. has a market cap of $14.46B USD, ranking #1252 globally and #73 in India. It ranks #104 in the Healthcare sector, and #11 in the Drug Manufacturers - Specialty & Generic industry.
Global Rank
1252
Country Rank
73
Sector Rank
104
Industry Rank
11
Key Stats
Market Cap
$14.46BUSD
1.23T INR
Enterprise Value
$13.48BUSD
1.15T INR
Revenue (TTM)
$3.13BUSD
267.2B INR
EBITDA (TTM)
$785.71MUSD
67.18B INR
Net Income (TTM)
$584.75MUSD
49.9B INR
EBITDA Margin
25%
Profit Margin
19%
PE Ratio
24.8
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Umang Vohra open_in_new
Employees
27,764
Founded
1935
Website
cipla.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
0.4% 2.8% -0.1% 6.7% 0% 13%
Upcoming Earnings
Earnings Date
Tue, May 13

Markets

Exchange Ticker Price
National Stock Exchange of India
MIC: XNSE
PRIMARY
CIPLA
Cipla Ltd
ISIN: INE059A01026
Shares Out.:
807.617M1 Shares Float: 533.752M2
TV:
SA:
YF:
GF:
BA:
MS:
1.53K INR
Bombay Stock Exchange
MIC: XBOM
500087 (CIPLA)
Cipla Ltd
ISIN: INE059A01026
TV:
SA:
YF:
GF:
BA:
MS:
1.51K INR
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Cipla Ltd.

Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women’s health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Similar Companies

Industry: Drug Manufacturers - Specialty & Generic (India)
Name
Market Cap diff.
Sun Pharmaceutical Industries Ltd.
SUNPHARMA
$49.13B
4.19T INR
240%
Divi's Laboratories Ltd.
DIVISLAB
$18.39B
1.57T INR
27%
Torrent Pharmaceuticals Ltd.
TORNTPHARM
$13.23B
1.13T INR
-8.6%
Mankind Pharma Ltd.
MANKIND
$12.47B
1.06T INR
-14%
Dr. Reddy's Laboratories Ltd.
DRREDDY
$11.47B
978.83B INR
-21%
Industry: Drug Manufacturers - Specialty & Generic (Global)
Name
Market Cap diff.
Zoetis Inc.
ZTS
$67.32B
365%
Merck KGaA
MRK
$59.42B
52.43B EUR
311%
Takeda Pharmaceutical Company Ltd.
4502
$46.31B
6.6T JPY
220%
Haleon plc
HLN
$45.57B
34.34B GBP
215%
Galderma Group AG
GALD
$23.06B
19.13B CHF
59%